CELLSEARCH® Circulating Tumor Cell Test in metastatic prostate cancer (mPC)—clinical trials and real-world case studies

Pivotal Clinical Trial—circulating tumor cells (CTCs) predict disease progression and survival in patients with mPC*1,2

Study design

Two hundred thirty-one patients with histologically confirmed mPC who were starting a new line of therapy were monitored with CTCs and prostate-specific antigen (PSA) levels at baseline and monthly thereafter.1

Results

OS in mPC Patients with CTCs <5 vs ≥5 at Baseline (N=219)
A Reduction in CTC to Below 5 After the Initiation of Therapy Predicts Longer OS
Ability of CTC and PSA Reduction to Predict OS
Ability of CTC and PSA Reduction to Predict OS

References: 
  1. de Bono, JS, et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2008;14:6302-6309.
  2. CELLSEARCH® Circulating Tumor Cell Kit (Epithelial) Instructions for Use. Janssen Diagnostics, LLC.